Departments

Make a gift to the EVMS Foundation
Text size
  • Decrease font size
  • Default font size
  • Increase font size

EVMS Strelitz Diabetes Center Research: Kaiwen Ma, PhD Print E-mail
Share

Ma-KaiwenKaiwen Ma, PhD
Research Instructor, Department of Internal Medicine

Dr. Ma received her post-doctoral training at the University of Virginia and joined EVMS in 2008.

The onset of diabetes is due to several pathological changes, which are an indication of either the failure of the pancreatic beta cells to secrete insulin to combat the hyperglycemia of insulin resistance in target tissues. Dr. Ma aims to understand the mechanisms of alterations in beta cell mass and decreased beta cell proliferation or growth in progression of diabetes. Her research also aims to understand the role of 12-lipoxygenase in beta cell cycle regulation.

Dr. Ma has presented at major international professional meetings and published key papers in peer-reviewed journals including The Journal of Clinical Endocrinology and Metabolism and Diabetes.

Selected Publications

  • Anca D. Dobrian , David C. Lieb , Qian Ma, John W. Lindsay , Banumathi K. Cole, Kaiwen Ma, Swarup K. Chakrabarti , Norine S. Kuhn , Stephen D. Wohlgemuth , Mark Fontana , Jerry L. Nadler.  Differential expression and localization of 12/15 lipoxygenases in adipose tissue in human obese subjects. Biochemical and Biophysical Research Communications. Volume 403, Issues 3-4, 17 December 2010, Pages 485-490
  • Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, Coben JM, Galkina EV, Nadler JL. Dipeptidyl peptidase-4 inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab. 2010 Nov 16. 
  • Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 12-Lipoxygenase products reduce insulin secretion and beta cell viability in human islets. J Clin Endocrinol Metab. 2010 Feb;95(2):887-93. Epub 2010 Jan 20.
  • McDuffie M, Maybee NA, Keller, SR, Stevens BK, Garmey JC, Morris MA, Kropf E, Rival C, Ma K, Carter JD, Tersey SA, Nunemaker CS, and Nadler JL. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes. 57(1): 199-208, 2008.
  • Ma K, Zheng S, Zuo Z. The transcription factor regulatory factor X1 increases the expression of neuronal glutamate transporter type 3.  J Biol Chem. 2006 Jul 28;281(30):21250-5. Epub 2006 May 24.
  • Goss VL, Cross JV, Ma K, Qian Y, Mola PW, Templeton DJ. SAPK/JNK regulates cdc2/cyclin B kinase through phosphorylation and inhibition of cdc25c. Cell Signal. 2003 Jul;15(7):709-18.
  • Ma K, Araki K, Ichwan SJ, Suganuma T, Tamamori-Adachi M, Ikeda MA. E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53. Mol Cancer Res. 2003 Apr;1(6):438-44.
  • Kaiwen Ma. [Involvement of E2FBP1, an ARID family member protein, in the p53 regulatory pathway] Kokubyo Gakkai Zasshi. 2002 Jun;69(2):152-61. Japanese.
  • Zhang YW, Morita I, Ikeda M, Ma KW, Murota S. Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene. 2001 Jul 12;20(31):4138-49.

 

 

 
Last Updated on Friday, 13 May 2011 16:00